[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574466":3},{"organization":4,"armGroups":7,"interventions":31,"overallOfficials":37,"centralContacts":42,"locations":48,"responsibleParty":207,"collaborators":209,"id":212,"slug":213,"hasResults":214,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":37,"eligibilityCriteria":218,"healthyVolunteers":214,"sex":219,"minAge":220,"maxAge":37,"enrollmentInfo":221,"targetDuration":37,"studyType":224,"phases":225,"briefSummary":227,"conditions":228,"keywords":231,"overallStatus":51,"whyStopped":37,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":245},{"fullName":5,"class":6},"Compugen Ltd","INDUSTRY",[8,14,18,23,27],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1, A-1","EXPERIMENTAL","Monotherapy Dose Escalation",[13],"Drug: COM503",{"label":15,"type":10,"description":16,"interventionNames":17},"Part 1, A-2","Backfill",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Part 1, B","Dose escalation, COM503 in combination with a fixed dose of zimberelimab.",[13,22],"Drug: Zimberelimab",{"label":24,"type":10,"description":25,"interventionNames":26},"Part 2, A","Dose expansion, COM503 monotherapy",[13],{"label":28,"type":10,"description":29,"interventionNames":30},"Part 2, B","Dose expansion, COM503 in combination with a fixed dose of zimberelimab.",[13,22],[32,38],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"DRUG","COM503","Intravenous Infusion",[9,15,19,24,28],null,{"type":33,"name":39,"description":40,"armGroupLabels":41,"otherNames":37},"Zimberelimab","Intravenous infusion",[19,28],[43],{"name":44,"role":45,"phone":46,"phoneExt":37,"email":47},"Michelle Chief Medical Officer, MD","CONTACT","+14153734034","michellebm@cgen.com",[49,68,82,97,112,127,137,152,168,181,194],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Yale- New Haven Hospital- Yale Cancer Center","RECRUITING","New Haven","Connecticut","06510","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-72.92816,41.30815,{"lat":61,"lon":60},[64],{"name":65,"role":45,"phone":66,"phoneExt":37,"email":67},"Study Coordinator","2038154124","omowunmi.afolabi@yale.edu",{"facility":69,"status":51,"city":70,"state":71,"zip":72,"country":55,"countryCode":56,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Beth Israel Deaconess Medical Center","Boston","Massachusetts","0221502215",{"type":58,"coordinates":74},[75,76],-71.05977,42.35843,{"lat":76,"lon":75},[79],{"name":37,"role":45,"phone":80,"phoneExt":37,"email":81},"6179757423","aposner1@bidmc.harvard.edu",{"facility":83,"status":51,"city":84,"state":85,"zip":86,"country":55,"countryCode":56,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"START Midwest","Grand Rapids","Michigan","49546",{"type":58,"coordinates":88},[89,90],-85.66809,42.96336,{"lat":90,"lon":89},[93],{"name":94,"role":45,"phone":95,"phoneExt":37,"email":96},"Manish Sharma","6169545554","manish.sharma@startmidwest.com",{"facility":98,"status":51,"city":99,"state":100,"zip":101,"country":55,"countryCode":56,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"The West Clinic, PLCC dba West Cancer Center","Germantown","Tennessee","38138",{"type":58,"coordinates":103},[104,105],-89.81009,35.08676,{"lat":105,"lon":104},[108],{"name":109,"role":45,"phone":110,"phoneExt":37,"email":111},"Manager of Phase 1 Research","9016830055","nholloway@westclinic.com",{"facility":113,"status":51,"city":114,"state":115,"zip":116,"country":55,"countryCode":56,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"NEXT Oncology San Antonio","San Antonio","Texas","78229",{"type":58,"coordinates":118},[119,120],-98.49363,29.42412,{"lat":120,"lon":119},[123],{"name":124,"role":45,"phone":125,"phoneExt":37,"email":126},"David Sommerhalder","2105809500","dsommerhalder@nextoncology.com",{"facility":128,"status":51,"city":114,"state":115,"zip":116,"country":55,"countryCode":56,"cosmosGeoPoint":129,"geoPoint":131,"contacts":132},"START",{"type":58,"coordinates":130},[119,120],{"lat":120,"lon":119},[133],{"name":134,"role":45,"phone":135,"phoneExt":37,"email":136},"Drew Rasco","2105935250","drasco@startsa.com",{"facility":138,"status":51,"city":139,"state":140,"zip":141,"country":55,"countryCode":56,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"NEXT Oncology Virginia","Fairfax","Virginia","22031",{"type":58,"coordinates":143},[144,145],-77.30637,38.84622,{"lat":145,"lon":144},[148],{"name":149,"role":45,"phone":150,"phoneExt":37,"email":151},"Mohammed Salkeni","7037834510","msalkeni@nextoncology.com",{"facility":153,"status":51,"city":154,"state":155,"zip":156,"country":155,"countryCode":157,"cosmosGeoPoint":158,"geoPoint":162,"contacts":163},"Rambam Health Care Campus","Haifa","Israel","3109601","IL",{"type":58,"coordinates":159},[160,161],34.99928,32.81303,{"lat":161,"lon":160},[164],{"name":165,"role":45,"phone":166,"phoneExt":37,"email":167},"Sudy Coordinator","97247776238","l_rapaport@rambam.health.gov.il",{"facility":169,"status":51,"city":170,"state":155,"zip":171,"country":155,"countryCode":157,"cosmosGeoPoint":172,"geoPoint":176,"contacts":177},"Hadassah University Medical Center- Ein Kerem","Jerusalem","9112001",{"type":58,"coordinates":173},[174,175],35.21633,31.76904,{"lat":175,"lon":174},[178],{"name":65,"role":45,"phone":179,"phoneExt":37,"email":180},"972509010225","ORITCOHEN@hadassah.org.il",{"facility":182,"status":51,"city":183,"state":155,"zip":184,"country":155,"countryCode":157,"cosmosGeoPoint":185,"geoPoint":189,"contacts":190},"Rabin Medical Center","Petah Tikva","4941492",{"type":58,"coordinates":186},[187,188],34.88747,32.08707,{"lat":188,"lon":187},[191],{"name":65,"role":45,"phone":192,"phoneExt":37,"email":193},"972524632668","yafitso1@clalit.org.il",{"facility":195,"status":51,"city":196,"state":155,"zip":197,"country":155,"countryCode":157,"cosmosGeoPoint":198,"geoPoint":202,"contacts":203},"The Chaim Sheba Medical Center","Ramat Gan","5465601",{"type":58,"coordinates":199},[200,201],34.81065,32.08227,{"lat":201,"lon":200},[204],{"name":65,"role":45,"phone":205,"phoneExt":37,"email":206},"972353304498","ilanit.redinsky@sheba.health.gov.il",{"type":208,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR",[210],{"name":211,"class":6},"Gilead Sciences","100574466","phase-1-a-clinical-trial-to-assess-com503-in-participants-with-advanced-solid-malignancies-100574466",false,"NCT06759649","A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies","A First-in-Human, Phase 1 Dose Escalation and Dose Expansion Trial to Assess the Safety and Tolerability of COM503 as Monotherapy and in Combination Therapy in Participants With Advanced Solid Malignancies","Inclusion Criteria:\n\n* Participants with histologically\u002Fcytologically confirmed advanced recurrent or metastatic solid tumor malignancy\n* Part 1 (dose escalation): Participants must have had disease progression on or following all available standard of care (SOC) therapies known to confer clinical benefit.\n* Part 2 (dose expansion): Participants may be enrolled following disease progression that has progressed after at least 1 available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized SOC.\n* Participants must have a solid tumor measurable by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria by investigator assessment\n\nExclusion Criteria:\n\n* History of another malignancy within 2 years prior to the first trial intervention administration (unless the malignancy was treated with curative intent with low risk of recurrence \\[e.g., nonmelanoma skin cancer, histologically confirmed complete excision of carcinoma in situ, or similar\\] which are allowed to enroll).\n* Therapy with Immunosuppressive doses of systemic medications, such as steroids (doses \\>10 mg\u002Fday prednisone or equivalent daily) within 2 weeks before trial intervention administration\n* Have known active central nervous system (CNS) metastases and\u002For leptomeningeal disease (LMD).\n* Active and clinically relevant bacterial, fungal, or viral infection that is not controlled or requires systemic antibiotics, antifungals, or antivirals, respectively.\n* Ascites or pleural effusion that is symptomatic and\u002For requiring drainage within 2 weeks prior to the first trial intervention administration.\n* Have active hepatitis B virus (HBV) or hepatitis C virus (HCV), or participants with human immunodeficiency virus (HIV).\n* Any medical condition that, in the investigator's or sponsor's opinion, poses an undue risk to the participant's participation in the trial.","ALL","18 Years",{"count":222,"type":223},200,"ESTIMATED","INTERVENTIONAL",[226],"PHASE1","The overall goal of this first-in-human (FIH) clinical trial is to learn about the safety and dosing of COM503 when given alone or in combination with zimberelimab in participants with advanced solid tumors.\n\nThe primary objectives of this study are:\n\n* To assess the safety and tolerability of COM503 as monotherapy and COM503 in combination with zimberelimab in participants with advanced solid tumors.\n* To identify the maximum tolerated dose (MTD) \u002F maximum administered dose (MAD) and\u002For the recommended phase 2 dose (RP2D) of COM503 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors.",[229,230],"Neoplasm","Cancer, Malignant Tumors",[232,233,234,235],"first-in-human","oncology","monoclonal antibody","immunotherapy","2026-02-26",{"date":238,"type":239},"2026-02-27","ACTUAL",{"date":241,"type":239},"2025-01-07",{"date":243,"type":223},"2027-11-22",{"name":5,"class":6},11]